Related Experiment Videos
[Osteogenesis imperfecta: a new, early therapeutic approach with biphosphonates. A case report]
M Guillot1, P Eckart, H Desrosieres
1Service de pédiatrie, centre hospitalier Robert-Bisson, BP 223, 14107 Lisieux, France.
Insights
Early pamidronate treatment for type III osteogenesis imperfecta (brittle bone disease) in infants shows promising results. This approach improves bone health and clinical outcomes in young children with severe O.I.
Area of Science:
- Pediatric Orthopedics
- Pharmacology
- Genetics
Background:
- Osteogenesis Imperfecta (O.I.), or brittle bone disease, is a genetic disorder characterized by fragile bones.
- Type III O.I. represents a severe form, historically managed with supportive care.
- Early intervention strategies are crucial for improving long-term outcomes.
Observation:
- A 6-month-old infant with severe type III O.I. presented with significant pain and fractures.
- The infant received cyclic intravenous disodium pamidronate therapy.
- Preliminary data indicated potential benefits, necessitating further investigation.
Findings:
- Pamidronate administration led to significant improvements in clinical status, including reduced fracture incidence, pain, and enhanced growth.
- Biological markers of bone health, such as bone density and osseous alkaline phosphatases, showed positive changes.
- Urinary desoxypyridoline excretion decreased, indicating reduced bone resorption.
Implications:
- Intravenous pamidronate is a promising therapeutic agent for severe type III O.I.
- Early administration, ideally within the first months of life, maximizes efficacy.
- Biphosphonates offer a new, effective treatment option with demonstrated clinical safety and ease of administration.
Unlabelled:
Management of type III osteogenesis imperfecta (O.I.) (brittle bone disease) is primarily supportive; early introduction of cyclic intravenous pamidronate administration in children younger than 2 years of age is an innovative and promising therapeutic approach.
Case Report:
We present the case of a 6-month-old infant, whose preliminary data have already been partly published, with severe type III O.I. referred because of aching and crumbling from multiple fractures. Cyclic intravenous disodic pamidronate administration improved the clinical status (fracture incidence, pain, growth curve) and biological status (bone density, osseous alkaline phosphatases, urinary desoxypiridoline excretion), allowing a remarkable recovery.
Conclusion:
Biphosphonates are a new and innovative therapeutic agent in O.I. Clinical safety, easy administration, and overall efficacy are likely to extend their use in severe type III O.I. from the very first months of life, the time of best efficacy.